lp-a.org

Testing

FRENCHIE-Lp(a) cohort shows one-third of patients with acute myocardial infarction shift Lp(a) categories over time, with a discharge threshold of ≤37 mg/dL limiting misclassification to <1% (Eur J Prev Cardiol 2026)

Original title: Variability of lipoprotein(a) levels in patients with acute myocardial infarction between admission, discharge, and follow-up

Eur J Prev Cardiol · · 6

Simon T, Khani Bittar R, Rousseau A, Prunier F, Cayla G, Ferrari E, Lhermusier T, Berard L, Goube P, Lemesle G, Bouleti C, Cottin Y et al.

This cohort study of 1561 patients hospitalized for acute myocardial infarction measured Lp(a) mass at admission, discharge, and 3-12 months follow-up. Median Lp(a) remained stable at 13 mg/dL, yet 68.5% of patients shifted Lp(a) categories over time. Using a discharge threshold of ≤37 mg/dL, misclassification for follow-up Lp(a) >70 mg/dL fell to 0.97%, compared with 39.9% in those above this cutoff. This exploratory two-step testing strategy warrants external validation before routine adoption in clinical practice.

Read the paper (DOI)PubMed

Original abstract

Aims: Lipoprotein(a) [Lp(a)] is an established risk factor for atherosclerotic cardiovascular disease. Using Lp(a) concentrations measured during stable follow-up as the reference, we aimed to assess the temporal variability of Lp(a) after acute myocardial infarction (AMI) and to explore a pragmatic strategy for Lp(a) measurement.

Methods And Results: The FRENCHIE-Lp(a) cohort enrolled consecutive adults hospitalized for AMI in 21 centres. Lp(a) mass concentration, measured at admission, hospital discharge, and 3-12 months follow-up, was analysed both as a continuous and predefined categorical variable (≤20, >20-≤50, >50-≤70, >70 mg/dL). Assuming follow-up Lp(a) as the reference, we aimed to identify the threshold values that would allow us to accurately identify patients with Lp(a) > 70mg/dL, the threshold mostly used for patient selection in phase III trials of targeted Lp(a) therapies. A cumulative threshold analysis was performed to identify the Lp(a) value below which the misclassification rate (i.e. % of patients with follow-up Lp(a) > 70 mg/dL) remained <1%. Among 1561 patients (aged 61 ± 12 years; 21.3% women), median Lp(a) was 13 mg/dL at admission and remained stable over time (median difference overtime = 0 mg/dL). However, only 68.5% of patients remained in the same Lp(a) category overtime. In patients with discharge-Lp(a) ≤37 mg/dL (72.5% of the population), only 0.97% had Lp(a) >70 mg/dL at follow-up compared to 39.9% of those with discharge-Lp(a) >37 mg/dL.

Conclusion: Although the median Lp(a) level remained stable between admission and follow-up, one-third of AMI patients shifted within Lp(a) categories over time. Pending external validation, an exploratory two-step strategy based on Lp(a) measurement at discharge, followed by repeat testing in patients with Lp(a) >37 mg/dL, showed a misclassification rate below 1% for identifying patients potentially needing intervention.

Registration: Clinical trial Number: NCT04050956.

epidemiologyrisktesting

Summary written by lp-a.org from the published abstract; figures as published. Page updated 10 November 2026. Methods.